药物洗脱支架治疗冠状动脉支架内再狭窄的长期疗效观察  

Effect of Drug Eluting stent Implantation in the Treatment of Coronary Artery In-stent Restenosis in a Long-term Clinical Follow-up

作　　者：蒯铮[1] 樊冰[1] 卜丽萍[1] 钱菊英[1] 王齐兵[1] 葛雷[1] 葛均波[1] 

机构地区：[1]复旦大学附属中山医院心内科上海市心血管病研究所,上海200032

出　　处：《中国临床医学》2011年第5期611-612,共2页Chinese Journal of Clinical Medicine

摘　　要：目的:评价药物洗脱支架治疗支架内再狭窄的长期疗效。方法:经药物洗脱支架治疗的支架内狭窄患者63例,平均随访22个月,观察有无主要心脏不良事件发生。结果:63例患者中,主要心脏不良事件的发生率为46.5%,未发生支架内血栓形成及心肌梗死事件。药物洗脱支架治疗药物洗脱支架术后支架内再狭窄疗效优于金属裸支架术后支架内再狭窄。Logistic多因素分析显示,药物洗脱支架治疗支架内再狭窄的疗效与年龄、性别、病变严重程度、病变直径、原支架种类及药物支架涂层材料无显著相关。结论:药物洗脱支架治疗支架内再狭窄安全、有效。Objective：To evaluate the curative effect of drug eluting stent（DES） implantation in the treatment of in-stent restenosis（ISR）. Methods： A total of 63 patients were observed major adverse cardiac event （MACE） in the treatment of ISR after DES implantation during an average 22-month follow-up. Results： The MACE rate was 46.5% and no in-stent thrombosis or myocardial infraction occurred. The curative effect of post-DES ISR was better than post-bare metal stent（BMS）ISR. Logistic regression analysis revealed that there was no correlation between the tong-term curative effect and age, gender, severity of lesion, vessel diameter, the drug eluting material or the type of former stent implantation. Conclusions： DES implantation is a safety and useful method in the treatment of ISR.

关 键 词：药物洗脱支架 支架内再狭窄 主要心脏不良事件 

分 类 号：R541.4[医药卫生—心血管疾病]